Clear All
12482 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70710-1907-01 70710-1907 Hydrocortisone sodium succinate Hydrocortisone sodium succinate 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 9, 2026 In Use
70771-1966-01 70771-1966 Hydrocortisone sodium succinate Hydrocortisone sodium succinate 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous May 9, 2026 In Use
85766-0206-05 85766-0206 Triamcinolone Acetonide Triamcinolone Acetonide 200.0 mg/5mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intra-articular, Intramuscular May 7, 2026 In Use
68071-3999-03 68071-3999 Anastrozole Tablets Anastrozole 1.0 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 7, 2026 In Use
72162-2634-02 72162-2634 Decitabine Decitabine 50.0 mg/10mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous May 6, 2026 In Use
72162-2640-02 72162-2640 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous May 6, 2026 In Use
72162-2642-02 72162-2642 Plerixafor Plerixafor 24.0 mg/1.2mL Ancillary Therapy Immunostimulant Stem Cell Mobilizer Subcutaneous May 6, 2026 In Use
50268-0032-12 50268-0032 Abiraterone Acetate Abiraterone Acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral May 4, 2026 In Use
50881-0044-08 50881-0044 Ruxolitinib JAKAFI XR 44.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
83634-0208-10 83634-0208 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2026 In Use
50881-0033-08 50881-0033 ruxolitinib JAKAFI XR 33.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
81279-0117-60 81279-0117 Dexamethasone Dexamethasone 0.25 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral May 1, 2026 In Use
50881-0055-08 50881-0055 Ruxolitinib JAKAFI XR 55.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
84043-0100-30 84043-0100 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral May 1, 2026 In Use
50881-0022-08 50881-0022 Ruxolitinib JAKAFI XR 22.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
84043-0200-30 84043-0200 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, cereblon/CRBN Oral May 1, 2026 In Use
50881-0011-08 50881-0011 Ruxolitinib JAKAFI XR 11.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral May 1, 2026 In Use
00404-9771-02 00404-9771 Metoclopramide Hydrochloride METOCLOPRAMIDE 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Apr 30, 2026 In Use
55513-0160-21 55513-0160 Blinatumomab Blincyto Immunotherapy Monoclonal Antibody CD3 (T cells) and CD19 (B cells) Intravenous Apr 30, 2026 In Use
67046-1058-03 67046-1058 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Apr 28, 2026 In Use
67046-1379-03 67046-1379 PREDNISONE PREDNISONE 50.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Apr 27, 2026 In Use
00121-0882-51 00121-0882 Ondansetron Ondansetron 4.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 20, 2026 In Use
00310-1350-99 00310-1350 Osimertinib Tagrisso 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Apr 19, 2026 In Use
71335-2974-05 71335-2974 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 16, 2026 In Use
71335-2974-03 71335-2974 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Apr 16, 2026 In Use

Found 12482 results — Export these results